Complement C5 inhibition as sepsis therapy
补体 C5 抑制作为脓毒症治疗
基本信息
- 批准号:10420351
- 负责人:
- 金额:$ 63.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-09 至 2027-01-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAmplifiersAnaphylatoxinsAnimal ModelAnimalsAntibioticsAnticoagulantsAnticoagulationAntimicrobial EffectAspartate TransaminaseAttenuatedBacillus anthracisBacteremiaBacteriaBasic ScienceBiological MarkersBlood CirculationBlood Coagulation DisordersBlood Urea NitrogenC5a anaphylatoxin receptorCause of DeathCell DeathCessation of lifeCoagulation ProcessCombined Modality TherapyComplementComplement 3 ConvertaseComplement 3bComplement 5aComplement ActivationComplement Membrane Attack ComplexComplement component C5ComplexCreatinineDataDevelopmentDiseaseDisease ProgressionEarly treatmentEscherichiaEscherichia coliFunctional disorderGenus staphylococcusGoalsHemolysisHost DefenseHourImmune ToleranceImmune responseImpairmentIndividualInfectionInflammationInflammatory ResponseIntensive Care UnitsKidney FailureLeadLethal Dose 50LifeLipopolysaccharidesMediatingMediator of activation proteinModelingMultiple Organ FailureMyocardial dysfunctionOrganOrgan failurePapioPathogenesisPathway interactionsPatientsPeptidoglycanPhagocytosisPlasmaPlayProthrombin time assayRecoveryReperfusion InjuryRoleSavingsSepsisSepticemiaShockSignal TransductionStaphylococcus aureusSyndromeSystemTestingTherapeuticTimeTissuesVascular Diseasesactivation productantagonistbaseclinically relevantcomplement pathwayeffective therapyhypoperfusionimprovedimproved outcomeinhibiting antibodyinhibitorinnovationmicrobialnonhuman primatenovelnovel therapeuticspathogenpre-clinical researchpreservationpreventreceptorresponsesepticseptic patientssystemic inflammatory responsetargeted treatment
项目摘要
PROJECT SUMMARY
Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Sepsis is a
leading cause of death in intensive care units. The contact of pathogens with the intravascular compartment of
the host leads to systemic inflammation, wherein activation of the complement and coagulation systems plays
critical roles.
The objectives of this proposal are to investigate the role of complement activation and its crosstalk with
inflammation and coagulation to sepsis progression and multiple organ failure (MOF) and, whether blocking
complement activation at the C5 level could prevent MOF and improve the outcome of sepsis.
We will use clinically relevant models of sepsis caused by two of the most common pathogens, Escherichia coli
and Staphylococcus aureus to: (i) determine the contribution of complement and coagulation to pathogenesis
of microthrombosis, vascular dysfunction, organ failure and death; (ii) test stage-specific therapies targeting the
complement and coagulation cascades to provide organ protection and survival benefit in sepsis-induced
progressive MOF.
Successful completion of these aims will determine: (i) whether timed complement inhibition at the C5 level
could be used as an effective therapy for sepsis-induced MOF; (ii) if inhibition of C5a receptor-1 signaling could
attenuate disease progression and provide organ protection; (iii) if combination therapies employing early
treatment with an anticoagulant and a delayed treatment with a C5 inhibitor will provide synergistic protection
in cases of high septic bacteremia/shock.
Altogether, our project will combine basic and preclinical research to verify novel hypotheses on the
pathophysiology of both Gram-negative and Gram-positive sepsis, and test innovative approaches, which in
the long-term may save lives from this deadly disease with no specific cure.
项目总结
脓毒症是一种因宿主对感染的反应失调而导致的危及生命的器官功能障碍。败血症是一种
重症监护病房的主要死因。病原体与血管内隔膜的接触
宿主导致全身炎症,其中补体和凝血系统的激活起作用
关键角色。
这项建议的目的是研究补体激活的作用及其与
炎症和凝血对脓毒症进展和多器官功能衰竭(MOF)的影响
补体在C5水平的激活可以预防多器官功能衰竭,改善脓毒症的结局。
我们将使用两种最常见的病原体大肠杆菌引起的败血症的临床相关模型。
和金黄色葡萄球菌:(I)确定补体和凝血在发病中的作用
微血栓形成、血管功能障碍、器官衰竭和死亡;(2)针对
补体和凝血级联在脓毒症中提供器官保护和生存益处
进步的财政部。
这些目标的成功完成将决定:(I)C5水平的定时补体抑制
可作为脓毒症诱导的多器官功能衰竭的有效治疗方法;(Ii)如果抑制C5a受体-1信号转导可以
延缓疾病进展并提供器官保护;(3)如果早期采用综合疗法
使用抗凝剂治疗和延迟使用C5抑制剂治疗将提供协同保护
在高度败血症/休克的情况下。
总之,我们的项目将结合基础和临床前研究来验证关于
革兰氏阴性和革兰氏阳性脓毒症的病理生理学,并测试创新的方法,其中
从长远来看,这种致命的疾病可能会在没有特效药的情况下拯救生命。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FLOREA LUPU其他文献
FLOREA LUPU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FLOREA LUPU', 18)}}的其他基金
Discovery and Characterization of Novel Sepsis Proteome Biomarkers
新型脓毒症蛋白质组生物标志物的发现和表征
- 批准号:
10364288 - 财政年份:2021
- 资助金额:
$ 63.34万 - 项目类别:
COBRE: OK MED RES FOUND: CORE I: IN VITRO MICROSCOPY CORE
COBRE:确定医学研究成果:核心 I:体外显微镜核心
- 批准号:
8168454 - 财政年份:2010
- 资助金额:
$ 63.34万 - 项目类别:
EPCR, TAFI as Regulators of PMN/Endothelial Interaction
EPCR、TAFI 作为 PMN/内皮相互作用的调节剂
- 批准号:
7939125 - 财政年份:2009
- 资助金额:
$ 63.34万 - 项目类别:
相似海外基金
SBIR Phase II: Thermally-optimized power amplifiers for next-generation telecommunication and radar
SBIR 第二阶段:用于下一代电信和雷达的热优化功率放大器
- 批准号:
2335504 - 财政年份:2024
- 资助金额:
$ 63.34万 - 项目类别:
Cooperative Agreement
Interferometric and Multiband optical Parametric Amplifiers for Communications (IMPAC)
用于通信的干涉式和多频带光学参量放大器 (IMPAC)
- 批准号:
EP/X031918/1 - 财政年份:2024
- 资助金额:
$ 63.34万 - 项目类别:
Fellowship
Josephson Parametric Amplifiers using CVD graphene junctions
使用 CVD 石墨烯结的约瑟夫森参量放大器
- 批准号:
EP/Y003152/1 - 财政年份:2024
- 资助金额:
$ 63.34万 - 项目类别:
Research Grant
Semiconductor-based Terahertz Traveling Wave Amplifiers for Monolithic Integration
用于单片集成的半导体太赫兹行波放大器
- 批准号:
2329940 - 财政年份:2023
- 资助金额:
$ 63.34万 - 项目类别:
Standard Grant
OPTIME-PA: Optimal MMIC Design of E-Band Power Amplifiers for Satcom using Dedicated Measurements and Non-Linear Modelling
OPTIME-PA:使用专用测量和非线性建模的卫星通信 E 频段功率放大器的最佳 MMIC 设计
- 批准号:
10075892 - 财政年份:2023
- 资助金额:
$ 63.34万 - 项目类别:
Collaborative R&D
Optical Glass Amplifiers for High Capacity Networks
用于高容量网络的光学玻璃放大器
- 批准号:
538379-2018 - 财政年份:2022
- 资助金额:
$ 63.34万 - 项目类别:
Collaborative Research and Development Grants
Investigating the function of ZU5 domain-containing proteins as amplifiers of caspase activation
研究含有 ZU5 结构域的蛋白质作为 caspase 激活放大器的功能
- 批准号:
10681326 - 财政年份:2022
- 资助金额:
$ 63.34万 - 项目类别:
Investigating the function of ZU5 domain-containing proteins as amplifiers of caspase activation
研究含有 ZU5 结构域的蛋白质作为 caspase 激活放大器的功能
- 批准号:
10621402 - 财政年份:2022
- 资助金额:
$ 63.34万 - 项目类别:
Broadband Digital Doherty Amplifiers for Sub-6 GHz 5G wireless Applications
适用于 6 GHz 以下 5G 无线应用的宽带数字 Doherty 放大器
- 批准号:
573452-2022 - 财政年份:2022
- 资助金额:
$ 63.34万 - 项目类别:
Alliance Grants
TALENT – Tapered AmpLifiErs for quaNtum Technologies
人才 — 量子技术的锥形放大器
- 批准号:
10032436 - 财政年份:2022
- 资助金额:
$ 63.34万 - 项目类别:
Collaborative R&D